Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Trial Profile

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hepatitis A vaccine; Hepatitis B vaccine; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Rotavirus vaccine; Varicella vaccines
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 31 Jan 2019 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.
    • 31 Jan 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.
    • 29 Nov 2018 Planned End Date changed from 1 Jan 2021 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top